-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, Chia Tai Tianqing Pharmaceutical Group has entered the administrative examination and approval stage with the generic 4 types of lenvatinib mesylate capsules.
It is expected to be approved in the near future and won the first imitation in China.
Lenvatinib is an oral multi-target kinase inhibitor developed by Eisai, with global sales of approximately US$1.
4 billion in 2019.
It is expected to be approved in the near future and won the first imitation in China.
Lenvatinib is an oral multi-target kinase inhibitor developed by Eisai, with global sales of approximately US$1.
4 billion in 2019.
Lenvatinib is an oral multi-target kinase inhibitor developed by Eisai, which can inhibit vascular endothelial growth factor receptor (VEGFR) 1-3, fibroblast growth factor receptor (FGFR) 1-4, platelet-derived Growth factor receptor (PDGFR) α, RET and KIT and other targets.
According to data from Menet.
com, global sales of lenvatinib in 2019 are approximately US$1.
4 billion.
According to data from Menet.
com, global sales of lenvatinib in 2019 are approximately US$1.
4 billion.
Lenvatinib mesylate capsule was approved for marketing in China in September 2018.
It is used to treat unresectable hepatocellular carcinoma that has not received systemic treatment before.
It became the first domestically approved first-line treatment of advanced liver cancer in the past 10 years.
The drug broke the long-term monopoly of sorafenib in the first-line liver cancer market.
It is used to treat unresectable hepatocellular carcinoma that has not received systemic treatment before.
It became the first domestically approved first-line treatment of advanced liver cancer in the past 10 years.
The drug broke the long-term monopoly of sorafenib in the first-line liver cancer market.
According to data from Meinenet, in 2019, China's urban public hospitals , county-level public hospitals, urban community centers, township health centers (referred to as Chinese public medical institutions), and China's urban entity pharmacies terminal lentinib sales totaled more than 300 million yuan.
In December 2020, lenvatinib entered the national medical insurance catalog through negotiations, and the market size is expected to further expand.
In December 2020, lenvatinib entered the national medical insurance catalog through negotiations, and the market size is expected to further expand.
Registration application status of Lenvatinib mesylate capsules
Source: One-click search on Mi Nei.
com
com
At present the domestic market a total of 10 companies submitted cutting imatinib mesylate Oakland 4 of generic capsules listed applications involving CTTQ, Simcere, Qilu Pharmaceutical, Cologne Pharmaceutical, Shijiazhuang Pharmaceutical Group, Yangtze River Pharmaceutical and Ao Saikang Wait.
The registration status of lenvatinib mesylate capsules of Zhengda Tianqing Pharmaceutical Group has been changed to "under approval", which is expected to win the first imitation.
The registration status of lenvatinib mesylate capsules of Zhengda Tianqing Pharmaceutical Group has been changed to "under approval", which is expected to win the first imitation.
Source: Minet database
Recently, Chia Tai Tianqing Pharmaceutical Group has entered the administrative examination and approval stage with the generic 4 types of lenvatinib mesylate capsules.
It is expected to be approved in the near future and won the first imitation in China.
Lenvatinib is an oral multi-target kinase inhibitor developed by Eisai, with global sales of approximately US$1.
4 billion in 2019.
It is expected to be approved in the near future and won the first imitation in China.
Lenvatinib is an oral multi-target kinase inhibitor developed by Eisai, with global sales of approximately US$1.
4 billion in 2019.
Lenvatinib is an oral multi-target kinase inhibitor developed by Eisai, which can inhibit vascular endothelial growth factor receptor (VEGFR) 1-3, fibroblast growth factor receptor (FGFR) 1-4, platelet-derived Growth factor receptor (PDGFR) α, RET and KIT and other targets.
According to data from Menet.
com, global sales of lenvatinib in 2019 are approximately US$1.
4 billion.
According to data from Menet.
com, global sales of lenvatinib in 2019 are approximately US$1.
4 billion.
Lenvatinib mesylate capsule was approved for marketing in China in September 2018.
It is used to treat unresectable hepatocellular carcinoma that has not received systemic treatment before.
It became the first domestically approved first-line treatment of advanced liver cancer in the past 10 years.
The drug broke the long-term monopoly of sorafenib in the first-line liver cancer market.
It is used to treat unresectable hepatocellular carcinoma that has not received systemic treatment before.
It became the first domestically approved first-line treatment of advanced liver cancer in the past 10 years.
The drug broke the long-term monopoly of sorafenib in the first-line liver cancer market.
According to data from Meinenet, in 2019, China's urban public hospitals , county-level public hospitals, urban community centers, township health centers (referred to as Chinese public medical institutions), and China's urban entity pharmacies terminal lentinib sales totaled more than 300 million yuan.
In December 2020, lenvatinib entered the national medical insurance catalog through negotiations, and the market size is expected to further expand.
In December 2020, lenvatinib entered the national medical insurance catalog through negotiations, and the market size is expected to further expand.
Registration application status of Lenvatinib mesylate capsules
Source: One-click search on Mi Nei.
com
com
At present the domestic market a total of 10 companies submitted cutting imatinib mesylate Oakland 4 of generic capsules listed applications involving CTTQ, Simcere, Qilu Pharmaceutical, Cologne Pharmaceutical, Shijiazhuang Pharmaceutical Group, Yangtze River Pharmaceutical and Ao Saikang Wait.
The registration status of lenvatinib mesylate capsules of Zhengda Tianqing Pharmaceutical Group has been changed to "under approval", which is expected to win the first imitation.
The registration status of lenvatinib mesylate capsules of Zhengda Tianqing Pharmaceutical Group has been changed to "under approval", which is expected to win the first imitation.
Source: Minet database
Recently, Chia Tai Tianqing Pharmaceutical Group has entered the administrative examination and approval stage with the generic 4 types of lenvatinib mesylate capsules.
It is expected to be approved in the near future and won the first imitation in China.
Lenvatinib is an oral multi-target kinase inhibitor developed by Eisai, with global sales of approximately US$1.
4 billion in 2019.
It is expected to be approved in the near future and won the first imitation in China.
Lenvatinib is an oral multi-target kinase inhibitor developed by Eisai, with global sales of approximately US$1.
4 billion in 2019.
Lenvatinib is an oral multi-target kinase inhibitor developed by Eisai, which can inhibit vascular endothelial growth factor receptor (VEGFR) 1-3, fibroblast growth factor receptor (FGFR) 1-4, platelet-derived Growth factor receptor (PDGFR) α, RET and KIT and other targets.
According to data from Menet.
com, global sales of lenvatinib in 2019 are approximately US$1.
4 billion.
According to data from Menet.
com, global sales of lenvatinib in 2019 are approximately US$1.
4 billion.
Lenvatinib mesylate capsule was approved for marketing in China in September 2018.
It is used to treat unresectable hepatocellular carcinoma that has not received systemic treatment before.
It became the first domestically approved first-line treatment of advanced liver cancer in the past 10 years.
The drug broke the long-term monopoly of sorafenib in the first-line liver cancer market.
It is used to treat unresectable hepatocellular carcinoma that has not received systemic treatment before.
It became the first domestically approved first-line treatment of advanced liver cancer in the past 10 years.
The drug broke the long-term monopoly of sorafenib in the first-line liver cancer market.
According to data from Meinenet, in 2019, China's urban public hospitals , county-level public hospitals, urban community centers, township health centers (referred to as Chinese public medical institutions), and China's urban entity pharmacies terminal lentinib sales totaled more than 300 million yuan.
In December 2020, lenvatinib entered the national medical insurance catalog through negotiations, and the market size is expected to further expand.
Hospital hospital hospital pharmacy pharmacy pharmacyIn December 2020, lenvatinib entered the national medical insurance catalog through negotiations, and the market size is expected to further expand.
Registration application status of Lenvatinib mesylate capsules
Source: One-click search on Mi Nei.
com
com
At present the domestic market a total of 10 companies submitted cutting imatinib mesylate Oakland 4 of generic capsules listed applications involving CTTQ, Simcere, Qilu Pharmaceutical, Cologne Pharmaceutical, Shijiazhuang Pharmaceutical Group, Yangtze River Pharmaceutical and Ao Saikang Wait.
The registration status of lenvatinib mesylate capsules of Zhengda Tianqing Pharmaceutical Group has been changed to "under approval", which is expected to win the first imitation.
Enterprise business enterpriseThe registration status of lenvatinib mesylate capsules of Zhengda Tianqing Pharmaceutical Group has been changed to "under approval", which is expected to win the first imitation.
Source: Minet database
